Pharmacokinetics and metabolism of rifampin in humans
- PMID: 6356276
- DOI: 10.1093/clinids/5.supplement_3.s428
Pharmacokinetics and metabolism of rifampin in humans
Abstract
The unique pharmacokinetic properties of rifampin in humans are discussed in this review. These properties can be better understood by assuming the existence of two pharmacokinetic subsystems; one, the primary subsystem, regulates the time course of the concentration of the antimicrobial agent in the other, the secondary subsystem. The first subsystem includes the intestine and the liver (interconnected through the portal blood and the bile), and the second subsystem includes the tissues, kidneys, and blood of the circulatory system. The connection between the two subsystems in normal conditions is the hepatic veins. The rate of excretion of rifampin in human bile depends, although not exclusively, on its rate of transformation into the biologically active desacetyl derivative. The rate of metabolism increases over the first week(s) of treatment, which results in a corresponding increase of desacetylrifampin excretion in bile. The process is limited and, within a given range of single doses, a transport maximum can be identified. Doses in excess of those associated with the transport maximum generate a more than proportional increase in serum concentrations of the drug. Administration of rifampin causes proliferation of the smooth endoplasmic reticulum of the hepatocyte (probably due to glucuronidation of a fraction of rifampin). This observation explains some of the interactions of rifampin with endogenous and exogenous compounds. The unique distribution of rifampin in human tissues probably results from its capacity to cross biological membranes. Excretion of rifampin in urine does not seem to be associated with any active process.
Similar articles
-
Clinical pharmacokinetics of rifampicin.Clin Pharmacokinet. 1978 Mar-Apr;3(2):108-27. doi: 10.2165/00003088-197803020-00002. Clin Pharmacokinet. 1978. PMID: 346286 Review.
-
Treatment of chronic drug-resistant pulmonary tuberculosis with rifampin and ethambutol.Can Med Assoc J. 1972 Apr 22;106(8):884-8. Can Med Assoc J. 1972. PMID: 4623743 Free PMC article.
-
Pharmacokinetic study of rifampicin in biliary surgery.Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):105-9. Int J Clin Pharmacol Biopharm. 1978. PMID: 649226
-
Rifampin drug interactions.Arch Intern Med. 1984 Aug;144(8):1667-71. doi: 10.1001/archinte.144.8.1667. Arch Intern Med. 1984. PMID: 6380442 Review.
-
Proceedings: Kinetics of rifampicin and desacetyl-rifampicin in plasma, bile, and urine in humans and the effect of repeated administrations.Acta Pharm Suec. 1974 Dec;11(6):657-8. Acta Pharm Suec. 1974. PMID: 1136808 No abstract available.
Cited by
-
Predicting Drug-Drug Interactions Involving Rifampicin Using a Semi-mechanistic Hepatic Compartmental Model.Pharm Res. 2024 Apr;41(4):699-709. doi: 10.1007/s11095-024-03691-5. Epub 2024 Mar 22. Pharm Res. 2024. PMID: 38519815
-
An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions.Med Chem. 2024;20(3):268-292. doi: 10.2174/0115734064260853230926080134. Med Chem. 2024. PMID: 37855280 Review.
-
Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations.Int J Mol Sci. 2023 Apr 3;24(7):6663. doi: 10.3390/ijms24076663. Int J Mol Sci. 2023. PMID: 37047633 Free PMC article. Review.
-
Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis.Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0147422. doi: 10.1128/aac.01474-22. Epub 2023 Feb 23. Antimicrob Agents Chemother. 2023. PMID: 36815838 Free PMC article.
-
Use of Novel Strategies to Develop Guidelines for Management of Pyogenic Osteomyelitis in Adults: A WikiGuidelines Group Consensus Statement.JAMA Netw Open. 2022 May 2;5(5):e2211321. doi: 10.1001/jamanetworkopen.2022.11321. JAMA Netw Open. 2022. PMID: 35536578 Free PMC article.